Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$226.31 -1.2%	$216.72	$163.81 ▼ $244.81	$404.77B	0.51	6.78 million shs	5.46 million shs
BMY Bristol Myers Squibb	$43.63 -0.4%	$46.16	$42.96 ▼ $63.33	$89.15B	0.33	19.34 million shs	11.94 million shs
LLY Eli Lilly and Company	$826.20 +1.7%	$745.96	$623.78 ▼ $935.63	$768.85B	0.47	3.94 million shs	2.35 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-1.26%	-2.14%	+3.85%	+18.33%	+17.96%
BMY Bristol Myers Squibb	-0.42%	-2.06%	-5.85%	-9.23%	-17.30%
LLY Eli Lilly and Company	+1.67%	-2.29%	+10.42%	+8.42%	-9.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$226.31 -1.2%	$216.72	$163.81 ▼ $244.81	$404.77B	0.51	6.78 million shs	5.46 million shs
BMY Bristol Myers Squibb	$43.63 -0.4%	$46.16	$42.96 ▼ $63.33	$89.15B	0.33	19.34 million shs	11.94 million shs
LLY Eli Lilly and Company	$826.20 +1.7%	$745.96	$623.78 ▼ $935.63	$768.85B	0.47	3.94 million shs	2.35 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-1.26%	-2.14%	+3.85%	+18.33%	+17.96%
BMY Bristol Myers Squibb	-0.42%	-2.06%	-5.85%	-9.23%	-17.30%
LLY Eli Lilly and Company	+1.67%	-2.29%	+10.42%	+8.42%	-9.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.71	Moderate Buy	$231.90	2.47% Upside
BMY Bristol Myers Squibb	2.33	Hold	$57.14	30.97% Upside
LLY Eli Lilly and Company	2.68	Moderate Buy	$948.06	14.75% Upside

Current Analyst Ratings Breakdown

Latest BMY, ABBV, and LLY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/14/2025	ABBV AbbVie	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
10/14/2025	BMY Bristol Myers Squibb	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
10/14/2025	LLY Eli Lilly and Company	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy
10/13/2025	BMY Bristol Myers Squibb	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
10/13/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
10/10/2025	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$231.00 ➝ $284.00
10/10/2025	LLY Eli Lilly and Company	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$876.00 ➝ $879.00
10/9/2025	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Overweight	$925.00
10/9/2025	ABBV AbbVie	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Overweight	$250.00
10/8/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$875.00 ➝ $948.00
10/8/2025	ABBV AbbVie	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)

(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	7.10	$14.74 per share	15.35	$1.90 per share	119.11
BMY Bristol Myers Squibb	$48.30B	1.84	$5.86 per share	7.44	$8.08 per share	5.40
LLY Eli Lilly and Company	$45.04B	17.36	$14.48 per share	57.07	$15.03 per share	54.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.10	107.77	16.19	1.48	6.45%	699.66%	13.64%	10/31/2025 (Estimated)
BMY Bristol Myers Squibb	-$8.95B	$2.48	17.59	7.16	2.26	10.58%	80.04%	14.69%	10/30/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$15.30	54.00	26.55	1.16	25.91%	92.72%	16.89%	10/30/2025 (Estimated)

Latest BMY, ABBV, and LLY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/31/2025	Q3 2025	ABBV AbbVie	$3.26	N/A	N/A	N/A	$15.58 billion	N/A
10/30/2025	Q3 2025	BMY Bristol Myers Squibb	$1.65	N/A	N/A	N/A	$11.75 billion	N/A
10/30/2025	Q3 2025	LLY Eli Lilly and Company	$6.42	N/A	N/A	N/A	$16.09 billion	N/A
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
7/31/2025	Q2 2025	ABBV AbbVie	$3.24	$2.97	-$0.27	$0.52	$14.93 billion	$15.42 billion
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.07	$1.46	+$0.39	$0.64	$11.32 billion	$12.27 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	2.90%	N/A	312.38%	53 Years
BMY Bristol Myers Squibb	$2.48	5.68%	N/A	100.00%	17 Years
LLY Eli Lilly and Company	$6.00	0.73%	N/A	39.22%	11 Years

Latest BMY, ABBV, and LLY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/5/2025	ABBV AbbVie	quarterly	$1.64	2.9%	10/15/2025	10/15/2025	11/14/2025
9/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.46%	10/3/2025	10/3/2025	11/3/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.74	0.61
BMY Bristol Myers Squibb	2.54	1.21	1.11
LLY Eli Lilly and Company	1.86	1.28	1.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
BMY Bristol Myers Squibb	76.41%
LLY Eli Lilly and Company	82.53%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
BMY Bristol Myers Squibb	0.09%
LLY Eli Lilly and Company	0.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.23 million	Optionable

BMY, ABBV, and LLY Headlines

Recent News About These Companies

Erste Group Upgrades Eli Lilly (LLY) to Buy Following Strong First-Half Results

26 minutes ago | insidermonkey.com

Eli Lilly and Company (NYSE:LLY) Shares Up 1.7% on Analyst Upgrade

October 15 at 4:54 PM | marketbeat.com

Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead (LLY)

...

October 15 at 4:15 PM | marketbeat.com

Lilly’s Oral GLP-1 Bests Another Big Pharma Bestseller in Phase III Diabetes Trial

October 15 at 2:25 PM | biospace.comB

Eli Lilly oral weight loss drug orforglipron succeeds in late-stage trials for diabetes

October 15 at 2:25 PM | msn.com

Eli Lilly’s orforglipron bests Farxiga, padding oral GLP-1 case with pair of phase 3 diabetes wins

October 15 at 2:25 PM | fiercebiotech.comF

Lilly, battling skepticism, reinforces GLP-1 pill’s case with new study data

October 15 at 2:25 PM | biopharmadive.comB

Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs

October 15 at 1:51 PM | benzinga.com

Eli Lilly: Outstanding Orforglipron Data Reinforces Value Proposition

October 15 at 12:31 PM | seekingalpha.com

How LLY Stock Delivered $47 Billion To Shareholders

October 15 at 10:03 AM | forbes.com

Eli Lilly Stock: Elevated Momentum, Strong Analyst Backing, Near-Term Earnings Focus

October 15 at 9:51 AM | talkmarkets.com

Lilly's oral GLP-1 drug helps reduce blood sugar levels in late-stage trials

October 15 at 6:51 AM | reuters.com

Interchange Capital Partners LLC Sells 896 Shares of Eli Lilly and Company $LLY

October 15 at 6:51 AM | marketbeat.com

Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes

October 15 at 6:45 AM | prnewswire.com

Deroy & Devereaux Private Investment Counsel Inc. Cuts Stock Position in Eli Lilly and Company $LLY

October 15 at 6:43 AM | marketbeat.com

Eli Lilly and Company $LLY Shares Acquired by Mutual Advisors LLC

October 15 at 6:34 AM | marketbeat.com

Generali Asset Management SPA SGR Decreases Stock Holdings in Eli Lilly and Company $LLY

October 15 at 6:34 AM | marketbeat.com

Eli Lilly and Company $LLY Shares Purchased by Ritholtz Wealth Management

October 15 at 6:20 AM | marketbeat.com

Delap Wealth Advisory LLC Has $386,000 Stock Holdings in Eli Lilly and Company $LLY

October 15 at 6:10 AM | marketbeat.com

Harbour Investments Inc. Buys 3,074 Shares of Eli Lilly and Company $LLY

October 15 at 5:58 AM | marketbeat.com

AEGON ASSET MANAGEMENT UK Plc Decreases Stock Holdings in Eli Lilly and Company $LLY

October 15 at 5:49 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BMY, ABBV, and LLY Company Descriptions

AbbVie NYSE:ABBV

$226.31 -2.82 (-1.23%)

Closing price 10/15/2025 03:59 PM Eastern

Extended Trading

$226.04 -0.27 (-0.12%)

As of 10/15/2025 07:56 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Bristol Myers Squibb NYSE:BMY

$43.63 -0.17 (-0.39%)

Closing price 10/15/2025 03:59 PM Eastern

Extended Trading

$43.64 +0.01 (+0.03%)

As of 10/15/2025 07:59 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Eli Lilly and Company NYSE:LLY

$826.20 +13.85 (+1.71%)

Closing price 10/15/2025 03:59 PM Eastern

Extended Trading

$826.00 -0.20 (-0.02%)

As of 10/15/2025 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMY, ABBV, and LLY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMY, ABBV, and LLY Earnings

Compare Dividends

Latest BMY, ABBV, and LLY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMY, ABBV, and LLY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BMY, ABBV, and LLY Company Descriptions

AbbVie NYSE:ABBV

Bristol Myers Squibb NYSE:BMY

Eli Lilly and Company NYSE:LLY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMY, ABBV, and LLY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMY, ABBV, and LLY Earnings

Compare Dividends

Latest BMY, ABBV, and LLY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMY, ABBV, and LLY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BMY, ABBV, and LLY Company Descriptions

AbbVie NYSE:ABBV

Bristol Myers Squibb NYSE:BMY

Eli Lilly and Company NYSE:LLY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools